Leadership

MGEN $8.56   $(0.84) | (8.94)%

Leadership

Executive Leadership

William S. Marshall, Ph.D.
William S. Marshall, Ph.D.
President and Chief Executive Officer
William S. Marshall, Ph.D.

William S. Marshall, Ph.D., is miRagen’s President, Chief Executive Officer, Co-Founder and Director. Prior to establishing miRagen, Dr. Marshall was Vice President of Technology and Business Development for Bioscience at Thermo Fisher Scientific. In this role, he was responsible for leading technology assessment and strategic planning for the Thermo Fisher Biosciences Division, a unit with revenues of approximately $1 billion that manufactures and supplies a wide range of products and services across the general-chemistry and life-sciences arenas.

Dr. Marshall was one of the scientific founders of Dharmacon, Inc., which was acquired by Fisher Scientific International, serving as the Executive Vice President for Research and Operations and General Manager. Prior to joining Dharmacon, Dr. Marshall served in many capacities at Amgen, Inc., most recently as Associate Director of Research, Site Head for Research and Head of the Nucleic Acid and Peptide Technology Department. In these positions, he participated in a wide variety of therapeutic development approaches throughout the drug discovery process leading to the development of clinical candidates.

Dr. Marshall earned his B.S. in Biochemistry from the University of Wisconsin-Madison and his Ph.D. in Chemistry in the laboratory of Professor Marvin Caruthers at the University of Colorado at Boulder. He is author and co-author of over 50 research papers and 80 patents. Dr. Marshall currently serves on the Boards of BiOptix, Inc., and the Colorado BioScience Association.

Jason A. Leverone, C.P.A.
Jason A. Leverone, C.P.A.
Chief Financial Officer
Jason A. Leverone, C.P.A.

Jason A. Leverone, C.P.A., is miRagen’s Chief Financial Officer. In this capacity, he oversees the company’s financial, accounting, and operations functions. Prior to joining miRagen, Mr. Leverone was Senior Director of Finance and Controller for Replidyne, Inc., a publicly-traded biotechnology company. At Replidyne, he played an important role in completing the company’s initial public offering and executing its strategic sale to Cardiovascular Systems, Inc. Prior to joining Replidyne, Mr. Leverone was the Corporate Controller for CreekPath System, Inc., an international software development company. He commenced his professional career with the accounting firm of Ernst and Young LLP and served as an Audit Manager for Arthur Andersen LLP.

Mr. Leverone is a Certified Public Accountant and holds a Bachelor of Science in Business Administration from Bryant University in Smithfield, Rhode Island.

Adam Levy
Adam Levy
Chief Business Officer
Adam Levy Adam Levy is miRagen’s Chief Business Officer. Mr. Levy brings over 16 years of advisory experience primarily in the life sciences sector to miRagen. Prior to joining miRagen, he was a Senior Vice President at Wedbush Securities where he served since 2013 in the healthcare investment banking group. Mr. Levy has expertise in corporate strategy, M&A and partnering with experience in completing more than $30 billion in financing and advisory transactions. Prior to joining Wedbush, he held positions of increasing responsibility in investment banking at Merrill Lynch and Jefferies. Mr. Levy earned a B.S. in Applied Economics from Cornell University.
Paul Rubin
Paul Rubin
Executive Vice President of Research and Development
Paul Rubin

Dr. Rubin has 30 years of industry experience. Prior to joining miRagen, Dr. Rubin was Senior Vice President of Resarch and Development and Chief Medical Officer at XOMA. Ltd from 2011 – 2015. He was Chief Executive Officer of Resolvyx Pharmaceuticals, Inc. from 2007 to 2009 and President and Chief Executive Officer of Critical Therapeutics, Inc. from 2002 to 2007.

From 1996 to 2002, Dr. Rubin was associated with Sepracor, where he served as Senior Vice President, Development, and later as Executive Vice President, Research & Development. He was responsible for leading the successful development of many of Sepracor’s internally developed and approved products including Xopenex®, Lunesta®, Xopenex HFA® and Brovana®.

From 1993 to 1996, Paul held senior level positions at Glaxo-Wellcome Pharmaceuticals, most recently as Vice President of Worldwide Clinical Pharmacology and Early Clinical Development. He was associated with Abbott from 1987 to 1993, including as Vice President, Immunology and Endocrinology, where he successfully advanced zileuton, the first and only approved 5-lipoxygenase inhibitor, from discovery to approval for the treatment of asthma.

Dr. Rubin received a BA from Occidental College and his M.D. from Rush Medical College. He is board certified in internal medicine completing his post-graduate training at the University of Wisconsin Hospital and Clinics.

Board of Directors

Bruce L. Booth, D.Phil.
Bruce L. Booth, D.Phil.
Co-Founder and Chairman of the Board of Directors, miRagen Therapeutics
Partner, Atlas Venture
Bruce L. Booth, D.Phil.

Bruce Booth is a Partner at Atlas Venture where he focuses on novel biopharmaceuticals and therapeutic platforms. Bruce currently serves on the Boards of Atlas portfolio companies Bicycle, miRagen, Nimbus, ProtAffin and Zafgen. He also served on the Board or worked closely with portfolio companies Avila (acquired by Celgene in 2012), Prestwick (acquired by Biovail in 2008), Stromedix (acquired by Biogen Idec in 2012), along with a number of other therapeutics companies.

Previously, Bruce was an investor with Caxton Health Holdings and prior to that a consultant at McKinsey & Company, where he focused on R&D Productivity topics. As a British Marshall Scholar, Bruce earned a Doctorate in Molecular Immunology from the Oxford University, and received his Bachelor of Science degree summa cum laude in Biochemistry from the Pennsylvania State University. He serves as a member of UCB Pharma’s Scientific Advisory Board, among several other translational research advisory roles. Bruce is also a Trustee of the New York Academy of Medicine.

Bruce has authored numerous scientific papers and biotech venture capital review articles, including several in Nature Biotechnology, and he blogs about life science venture topics at LifeSciVC.com, which is also syndicated with Forbes.

John Creecy, M.S.
John Creecy, M.S.
Board of Directors member, miRagen Therapeutics
Chief Executive Officer, Remeditex Ventures, LLC
John Creecy, M.S.

Mr. Creecy is Chief Executive Officer and a Director of Remeditex Ventures, LLC, a biomedical investment company that seeks to build a robust biomedical industry in Texas and Colorado by investing in early-stage university projects and start-up companies located in those regions. Prior to joining Remeditex, Mr. Creecy served as President and Chief Executive Officer of Hunt Petroleum Corporation and prior to that was the Chief Operating Officer of the Hodges Companies, Inc.

For more than 20 years, Mr. Creecy has served in various board positions within the All Saints Health System in Ft. Worth, Texas, the UT Southwestern Medical Center, and the Baylor Health Systems in Dallas, Texas. In addition to miRagen, Mr. Creecy sits on the boards of the following biomedical industry companies: Apollo Endosurgery, Peloton Therapeutics, BiO2 Medical, VuComp, and BiOptix.

Mr. Creecy is a graduate of Texas Tech University with a Bachelor’s Degree in Accounting and holds a Master’s of Science Degree in Accounting from the University of North Texas. He is a former Certified Public Accountant and currently serves as a member of various business and civic organizations.

Thomas E. Hughes, Ph.D.
Thomas E. Hughes, Ph.D.
Board of Directors member, miRagen Therapeutics
Chief Executive Officer, Zafgen Inc.
Thomas E. Hughes, Ph.D.

Dr. Hughes has over 25 years of experience in pharmaceutical research and development. Dr. Hughes joined Zafgen in 2008 as president, chief executive officer, and a member of the company’s board of directors. From 1987 to 2008, Dr. Hughes held several positions at Novartis AG (and formerly Sandoz Pharmaceuticals) including vice president and global head of the cardiovascular and metabolic diseases therapeutic area at the Novartis Institutes for BioMedical Research in Cambridge, MA. In these roles, he oversaw many drug discovery and development projects targeting obesity, diabetes, and heart disease. As a scientist, Dr. Hughes led Novartis’ efforts to discover and develop its dipeptidylpeptidase IV inhibitor vildagliptin (Galvus®/Eucreas®), a drug used for the treatment of type 2 diabetes, currently approved in 70 countries. Dr. Hughes is the author of over 40 peer-reviewed publications and is an inventor on numerous issued and pending patents related to the treatment of diabetes, cardiovascular disease, and obesity.

Dr. Hughes serves as a director on the board of miRagen Therapeutics, Inc., and is a member of several scientific and strategic advisory boards, including Broadview Ventures and Nimbus Discovery, LLC.

Kyle Lefkoff, M.B.A.
Kyle Lefkoff, M.B.A.
Board of Directors member, miRagen Therapeutics
Founder and General Partner, Boulder Ventures Ltd.
Kyle Lefkoff, M.B.A.

Kyle Lefkoff is a Founder and General Partner of Boulder Ventures Ltd. Boulder Ventures manages five venture capital funds with over $300 million in committed capital. In his twenty-five year career as a venture capitalist, Mr. Lefkoff has invested in 60 Colorado companies, resulting in twelve IPOs and sixteen trade sales.

Mr. Lefkoff’s representative life science investments include Hauser Chemical Research (NASDAQ: HAUS); NeXstar Pharmaceuticals (sold to Gilead Sciences), Array BioPharma (NASDAQ: ARRY), Dharmacon (Sold to Fisher Scientific), Genomica (sold to Exelixis), ARCA BioPharma (NASDAQ: ARCA), Barofold, BiOptix, and miRagen Therapeutics.

Mr. Lefkoff is a Director of Metabolite Laboratories, miRagen Therapeutics, BiOptix, and Trust Company of America. He is the Chairman of the Board of Array BioPharma, and of BaroFold Inc. He is the past Chairman of the Venture Capital Association of Colorado and is an Adjunct Professor of Finance at the University of Colorado Leeds School of Business.

Mr. Lefkoff received his B.A. in Economics from Vassar College (summa cum laude) in 1981. In 1980, Mr. Lefkoff completed a Fellowship in Economic History at the London School of Economics. In 1985, he completed his MBA in Finance at the University of Chicago.

William S. Marshall, Ph.D.
William S. Marshall, Ph.D.
Co-Founder, member of Board of Directors, miRagen Therapeutics
President and CEO, miRagen Therapeutics
William S. Marshall, Ph.D.

William S. Marshall, Ph.D., is miRagen’s President, Chief Executive Officer, Co-Founder and Director. Prior to establishing miRagen, Dr. Marshall was Vice President of Technology and Business Development for Bioscience at Thermo Fisher Scientific. In this role, he was responsible for leading technology assessment and strategic planning for the Thermo Fisher Biosciences Division, a unit with revenues of approximately $1 billion that manufactures and supplies a wide range of products and services across the general-chemistry and life-sciences arenas.

Dr. Marshall was one of the scientific founders of Dharmacon, Inc., which was acquired by Fisher Scientific International, serving as the Executive Vice President for Research and Operations and General Manager. Prior to joining Dharmacon, Dr. Marshall served in many capacities at Amgen, Inc., most recently as Associate Director of Research, Site Head for Research and Head of the Nucleic Acid and Peptide Technology Department. In these positions, he participated in a wide variety of therapeutic development approaches throughout the drug discovery process leading to the development of clinical candidates.

Dr. Marshall earned his B.S. in Biochemistry from the University of Wisconsin-Madison and his Ph.D. in Chemistry in the laboratory of Professor Marvin Caruthers at the University of Colorado at Boulder. He is author and co-author of over 50 research papers and 80 patents. Dr. Marshall currently serves on the Boards of BiOptix, Inc., and the Colorado BioScience Association.

Kevin Koch, Ph.D.
Kevin Koch, Ph.D.
Venture Partner, OrbiMed Advisors
Kevin Koch, Ph.D. Kevin Koch, Ph.D., is a Venture Partner with OrbiMed Advisors, LLC. Dr. Koch has been active in the life science industry for 25+ years with a focus on drug discovery, translational medicine and clinical development. Most recently, Dr. Koch was the Senior Vice President of Drug Discovery: Chemical and Molecular Therapeutics at Biogen where he managed global drug discovery and biomarker development as well as the immunology and hematology teams. From 1998-2013, Dr. Koch served as the President, Chief Scientific Officer, Board member and Co-Founder of Array BioPharma, Inc. While there, he built a fully integrated R&D team that oversaw the invention of over 20 clinical development candidates in the multiple therapeutic areas. Prior to Array, Dr. Koch held senior positions at Amgen Inc. and Pfizer Central Research. Dr. Koch received a B.S. in Chemistry and Biochemistry from State University of New York, Stony Brook, and his Ph.D. in Organic Chemistry from University of Rochester. He is the co-author or inventor of over 80 patents and publications. Dr. Koch currently serves on the board of Encycle Therapeutics and a number of scientific advisory boards.
Joe Turner Jr.
Joe Turner Jr.
Board of Directors member, miRagen Therapeutics
Director BioClin Therapeutics
Joe Turner Jr.

Mr. Turner has served as an independent director and audit committee chair for multiple biotech companies over the last decade. He currently serves on the board of BioClin Therapeutics. In recent years, he has served on the boards of Corcept Therapeutics, Kythera Biotherapeutics, Alexza Pharmaceuticals, Nora Therapeutics, Sophiris Bio, QLT and SGX Pharmaceuticals.

Mr. Turner has served as an independent director and audit committee chair for multiple biotech companies over the last decade. He currently serves on the board of BioClin Therapeutics. In recent years, he has served on the boards of Corcept Therapeutics, Kythera Biotherapeutics, Alexza Pharmaceuticals, Nora Therapeutics, Sophiris Bio, QLT and SGX Pharmaceuticals.

Mr. Turner previously as served as the chief financial officer of Myogen, Inc. from 1999 until it was acquired by Gilead Sciences in 2006. Previously, he served as the chief financial officer of Centaur Pharmaceuticals from 1997 to 1999 and as the chief financial officer and vice president, finance and administration at Cortech, Inc. from 1992 to 1997. Prior to Cortech, he was employed by Eli Lilly from 1979 to 1991 in a variety of finance and administration roles.

Mr. Turner holds an MBA from University of North Carolina at Chapel Hill, an M.A. in molecular, cellular and developmental biology from University of Colorado and a B.A. in chemistry with a minor in biology from Swarthmore College. Since 2009, he has served on the board of managers of Swarthmore College where at various times he has served on its executive committee, finance committee, audit committee, academic affairs committee (which he currently chairs) and student affairs committee and property committee.